Association of serum interleukin-6 with negative symptoms in stable early-onset schizophrenia

BACKGROUND Accumulating evidence suggests that the inflammatory cytokine interleukin-6(IL-6)contributes to the pathophysiology of psychiatric disorders.However,there was no study concerning the relationship between IL-6 concentrations and clinical features in the chronic phase of early-onset schizophrenia(EOS).AIM To investigate the relationship between serum IL-6 concentration and the clinical features of EOS.METHODS We measured serum IL-6 Levels from 74 patients with chronic schizophrenia,including 33 with age at onset<21 years(EOS group)and 41 with onset≥21 years in[adult-onset schizophrenia(AOS)group],and from 41 healthy controls.Symptom severities were evaluated using the Positive and Negative Syndrome Scale(PANSS).RESULTS Serum IL-6 concentrations were higher in both EOS and AOS groups than healthy controls(F=22.32,P<0.01),but did not differ significantly between EOS and AOS groups(P>0.05)after controlling for age,body mass index,and other covariates.Negative symptom scores were higher in the EOS group than the AOS group(F=6.199,P=0.015).Serum IL-6 concentrations in the EOS group were negatively correlated with both total PANSS-negative symptom score(r=-0.389,P=0.032)and avolition/asociality subscore(r=-0.387,P=0.026).CONCLUSION Patients with EOS may have more severe negative symptoms than those with adult-onset schizophrenia during the chronic phase of the illness.IL-6 signaling may regulate negative symptoms and its avolition/asociality subsymptoms among the early-onset chronic schizophrenic patients.

Liquid Subcutaneous Levodopa-Carbidopa ND0612 Effects on Motor Symptoms in Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Objective: In the manuscript titled “Liquid subcutaneous Levodopa-Carbidopa ND0612 effects on motor symptoms in individuals with Parkinson’s Disease: A systematic review and meta-analysis”, the objective was to conduct a systematic review with meta-analysis to investigate the effects ND0612 24-hour dosing regimen has on motor symptoms in individuals with Parkinson’s Disease (PD). Introduction: ND0612 is a novel minimally invasive continuous subcutaneous delivery system of liquid Levodopa-Carbidopa being investigated for the treatment of PD in individuals experiencing motor symptoms. Methods: A systematic literature search was conducted in PubMed, Cochrane, and EBSCO databases to identify randomized controlled trials investigating the effects of ND0612 on motor symptoms in individuals with PD. Outcomes included the Unified Parkinson’s Disease Rating Scale (UPDRS) Part II and Part III scores. Methodological quality was assessed using the Cochrane Grading of Recommendations Assessment, Development, and Evaluation approach. Meta-analysis was performed using a random effects model with the DerSimonian and Laird method to estimate the effects of the ND0612 24-hour dosing regimen on UPDRS Part II and Part III scores. Results: Three studies were included in our review. There were statistically significant reductions in UPDRS Part II scores (mean difference (MD) −3.299;95% confidence interval (CI) −3.438, −3.159) and in UPDRS Part III scores (MD −12.695;95% CI −24.428, −0.962) in the ND0612 24-hour dosing regimen. Results were based on very low certainty of evidence. Conclusion: Based on very low certainty evidence, the ND0612 24-hour dosing regimen is effective at improving motor symptoms in individuals with PD. Our findings suggest that ND0612 is more effective at improving UPDRS Part II and Part III scores in individuals with PD than other pharmacological and non-pharmacological treatments, warranting further study.

Monoamine Oxidase-B Inhibitor Rasagiline Effects on Motor and Non-Motor Symptoms in Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Objective: In the manuscript titled Monoamine Oxidase-B Inhibitor Rasagiline Effects on Motor and Non-Motor Symptoms in Individuals with Parkinsons Disease: A Systematic Review and Meta-Analysis, the objective was to conduct a systematic review with meta-analysis to investigate the effects that Rasagiline has on motor and non-motor symptoms in individuals with PD. Introduction: Rasagiline is a second-generation monoamine oxidase-B (MAO-B) inhibitor used both as monotherapy and adjunctive therapy for Parkinsons Disease (PD). Methods: A systematic literature search and meta-analysis were performed with randomized control trials that investigated the effects of Rasagiline on motor and non-motor symptoms in individuals with PD. The systematic search was conducted in PubMed, Cochrane, and EBSCO databases. Methodological quality was assessed using the Cochrane Grading Recommendations Assessment, Development and Evaluation approach. Results: Fourteen studies were included in our review. There were trivial to small and statistically significant improvements in motor symptoms for individuals with PD treated with Rasagiline compared to placebo. Non-motor symptoms showed no significant improvement with Rasagiline compared to placebo in five of six meta-analyses. Results were based on very low to moderate certainty of evidence. Conclusion: 1 mg/day Rasagiline significantly improved Parkinsonian motor symptoms in individuals with PD compared with placebo. For all outcomes, the 1 mg/day Rasagiline group was favored over the placebo group.

Analysis of risk factors for postpartum depression after cesarean section in women with early-onset preeclampsia

BACKGROUND Early-onset preeclampsia significantly increases maternal and fetal morbidity and mortality.Many pregnant women with early onset preeclampsia choose cesarean section as their delivery method.Although extensive research has explored the association between postpartum depression(PPD)and cesarean section,few studies have investigated the risk factors after cesarean section in women with early-onset preeclampsia.AIM To examine these risk factors through a retrospective,observational analysis of 287 women who underwent a cesarean section for early preeclampsia between June 2014 and March 2024.METHODS Participants were assessed in person during the 32nd week of pregnancy,2 days post-cesarean,and 6 weeks postpartum.According to the Edinburgh Postnatal Depression Scale(EPDS),participants who underwent cesarean section were divided into PPD(n=60)and non-PPD groups(n=227).Furthermore,PPD was diagnosed at 6 weeks postpartum according to depressive symptoms(EPDS score≥11).The demographic and clinical features of PPD were screened.Multivariate logistic regression analysis was used to identify PPD risk factors.RESULTS The prevalence of PPD was 20.9%(60/287)among the 287 women who underwent cesarean section for early-onset preeclampsia.Multivariate logistic regression analyses revealed that advanced age(age>40 years)[odds ratio(OR)=1.93,95%CI:1.31-2.82],previous preeclampsia(OR=7.15,95%CI:5.81-8.85),pre-pregnancy obesity(OR=2.42,95%CI:1.62-3.63),gestational diabetes mellitus(OR=3.52,95%CI:2.51-4.92),preexisting hypertension(OR=1.35,95%CI:1.03-1.89),PPD symptoms(EPDS≥11)at 2 days postpartum(OR=6.15,95%CI:1.32-28.35),high prenatal self-rating anxiety scale score(OR=1.13,95%CI:1.06-1.18),and pain at 6 weeks postpartum(OR=2.16,95%CI:1.28-3.66)were independently associated with PPD.CONCLUSION Risk factors for PPD after cesarean section in women with early-onset preeclampsia include advanced age(age>40 years),pre-pregnancy obesity,previous preeclampsia,gestational diabetes mellitus,preexisting hypertension,PPD symptoms(EPDS≥11)at 2 days postpartum,prenatal anxiety,and pain at 6 weeks postpartum.The early identi-fication of these factors and interventions can mitigate the risk of PPD.

Effects of a Cocktail Supplement of Ginkgo Biloba and Acai Extract on Cognitive Symptoms of Parkinson’s Disease

Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms, including cognitive impairment. Current treatments often involve synthetic drugs with significant side effects and potential for dependency. This study investigates the effects of a natural supplement combination of Ginkgo Biloba and Acai Extract on cognitive symptoms in a 77-year-old male with PD. The participant underwent a three-month supplementation regimen, with cognitive function assessed using the Montreal Cognitive Assessment (MoCA) test before and after the intervention. The results indicated an improvement in cognitive scores, suggesting that the combination of Ginkgo Biloba and Acai Extract may offer a promising alternative or adjunct to conventional PD treatments. This study highlights the potential of natural supplements in managing PD symptoms and calls for further research with larger sample sizes to confirm these findings. Human data was performed in accordance with the Declaration of Helsinki by the Roxbury District IRB Board (IRB Number: IRB00011767).

Neuronal injury in the motor cortex after chronic stroke and lower limb motor impairment: a voxelbased lesion symptom mapping study

Many studies have examined motor impairments using voxel-based lesion symptom mapping, but few are reported regarding the corresponding relationship between cerebral cortex injury and lower limb motor impairment analyzed using this technique. This study correlated neuro- nal injury in the cerebral cortex of 16 patients with chronic stroke based on a voxel-based lesion symptom mapping analysis. Neuronal injury in the corona radiata, caudate nucleus and putamen of patients with chronic stroke could predict walking speed. The behavioral measure scores were consistent with motor deficits expected after damage to the cortical motor system due to stroke. These findings suggest that voxel-based lesion symptom mapping may provide a more accurate prognosis of motor recovery from chronic stroke according to neuronal injury in cerebral motor cortex.

Non-Motor Symptoms in Parkinson’s Disease Patients—An Observational Study

Background: Parkinson’s disease (PD) remains a challenge for neurologists, particularly in its advanced stages when non-motor symptoms become a burden for the patient. While motor symptoms may be satisfactorily controlled with levodopa therapy or continuous levodopa/carbidopa intestinal gel (LCIG) administration, autonomic, sleep and mental disorders are hard to treat. During the last years, researchers have shifted their interest more to non-motor symptoms, PD being now considered a complex multiorgan impairment. Objective: The aim of this study was to describe non-motor symptoms in 40 Romanian patients diagnosed with PD, under conventional and LCIG administration treatment. Methods: A cross-sectional observational study was conducted, consisting of two groups of 20 patients each: the first group comprised PD patients who received conventional Levodopa treatment, while the second group was formed of patients receiving LCIG therapy. Various data concerning patient’s age, gender, duration of illness, comorbidities, motor and non-motor symptoms were recorded. The data were processed in SPSS v.20. Results: Subjects under continuous LCIG administration, although showing amelioration of motor symptoms, complained more frequently of constipation, mental, and sleeping disorders (statistically significant). Regarding anosmia, orthostatic hypotension, hypersalivation, urinary incontinence and restless legs syndrome, no statistical significant difference was observed between the two groups (p > 0.05). Conclusion: Nowadays, more research is conducted on non-motor symptoms in PD patients, as therapeutic measures try to limit these burdens, in order to improve patient’s quality of life.

Non-motor signs and symptoms in Parkinson’s disease

Motor symptoms are cardinal clinical features of Parkinson’s disease (PD). Progress in drug therapy and rehabilitation has been presenting beneficial effect for motor symptoms. However, non-motor symptoms and signs in PD have been accumulated growing attentions and its amelioration may also give beneficial effect for PD patients’ and their care givers’ quality of life. In this mini-review, I overviewed non-motor symptoms and signs in PD.

帕金森病神经突触损伤及中药干预研究进展

帕金森病(PD)是一种常见的神经退行性疾病,临床表现主要分为运动症状和非运动症状。运动症状是PD的终末核心特征之一,与黑质致密部多巴胺能神经元丢失直接相关。而PD运动症状出现之前往往会表现出嗅觉障碍、视觉障碍、睡眠障碍、抑郁、认知障碍等非运动症状,严重影响患者的生活质量。这些症状的产生与大脑特定部位神经突触损伤及功能变化有关,围绕PD突触损伤进行早期诊断和干预是防止PD进行性加重的重要环节。传统中医药在治疗神经退行性疾病方面具有丰富的理论知识和临床经验,中药是常用手段,且其对突触保护凸显出独特的作用。本文综述了神经突触损伤在PD相关症状发生发展过程中扮演的角色,突触损伤的机制和中药对突触损伤的干预作用及潜在机制,以期为神经退行性疾病的有效防治提供新的思路。

平肝熄风汤辅助治疗对帕金森伴抑郁患者非运动症状、睡眠质量和抑郁症状的影响

目的探讨平肝熄风汤辅助治疗对帕金森伴抑郁患者非运动症状、睡眠质量和抑郁症状的影响。方法选取2021年1月至2022年1月在本院确诊的98例帕金森伴抑郁患者,采用随机数字表法将其分为平肝熄风组和对照组,每组49例。对照组患者采用多巴丝肼、普拉克索片和曲唑酮治疗,平肝熄风组在对照组的基础上采用平肝熄风汤辅助治疗。两组均持续治疗24周。分别于治疗前后,比较两组的非运动症状、睡眠质量和抑郁症状。结果治疗后平肝熄风组NMSS评分中除认知方面评分,其他方面评分均低于对照组(P<0.05)。平肝熄风组治疗后第10、12、24周PSQI和HAMD评分均低于对照组(P<0.05)。平肝熄风组不良反应发生率为12.24%,对照组为24.49%,组间差异无统计学意义(P>0.05)。结论平肝熄风汤辅助治疗对帕金森伴抑郁患者非运动症状、睡眠质量和抑郁症状都有较好的改善效果。

广西地区幽门螺杆菌感染与帕金森病患者运动症状严重程度相关性研究

分析广西地区幽门螺杆菌感染与帕金森病患者运动症状严重程度的相关性。将广西科技大学第一附属医院2022年1月—2023年12月收治的70例帕金森病患者纳入试验组,将广西科技大学第一附属医院同期的70例健康人员纳入参照组。对组间人员基本资料进行收集,实施碳-14尿素呼气试验,进行UPDRS PartⅢ评分,研究幽门螺杆菌感染与帕金森病患者血清维生素B12、帕金森病评定量表评分之间的相关性。结果显示,试验组的碳-14尿素呼气试验中幽门螺杆菌阳性率高于参照组(P<0.05);试验组和参照组的血清维生素B12水平比较,无统计学差异(P>0.05);试验组中幽门螺杆菌阳性组和阴性组的血清维生素B12水平比较,无统计学差异(P>0.05);幽门螺杆菌阳性组的UPDRS PartⅢ评分高于阴性组,组间数据差异具有统计学意义(P<0.05)。研究发现,感染幽门螺杆菌易加重帕金森病患者的运动症状,两者之间关系密切,值得探讨。

帕金森病、特发性震颤患者的震颤分析及非运动症状差异

目的:分析帕金森病、特发性震颤患者震颤分析、非运动症状差异及其影响因素。方法:将2022年3月~2023年3月我院收治的帕金森病患者82例纳入帕金森组,特发性震颤患者68例纳入特发性震颤组,回顾性收集患者临床资料。分析两组一般资料、震颤分析及非运动症状差异,并分析其影响因素。结果:年龄>60岁、震颤部位单侧肢体、谐波现象、嗅觉减退为帕金森病的危险因素(P<0.05),姿势震颤频率、周围波为帕金森病的保护因素(P<0.05)。结论:帕金森病、特发性震颤患者震颤分析、非运动症状存在差异,其影响因素较多,可为其临床鉴别提供依据。

普拉克索联合多巴丝肼治疗帕金森病患者的效果

目的:观察普拉克索联合多巴丝肼治疗帕金森病患者的效果。方法:选取2021年3月至2023年3月该院收治的86例帕金森病患者进行前瞻性研究,按随机数字表法将其分为研究组和对照组各43例,对照组予以多巴丝肼治疗,研究组在对照组基础上联合普拉克索治疗,比较两组临床疗效,治疗前后Hoehn-Yahr分级、非运动症状控制[非运动症状评价量表(NMSS)]评分、血清miR-124和miR-137水平、认知功能[蒙特利尔认知量表(MOCA)]评分和生命质量[帕金森患者生活质量问卷(PDQ-39)]评分,以及不良反应发生率。结果:研究组治疗总有效率为95.35%(41/43),高于对照组的81.40%(35/43),差异有统计学意义(P<0.05);治疗后,研究组Hoehn-Yahr分级优于对照组,差异有统计学意义(P<0.05);研究组病情严重程度、发生频率等NMSS评分均低于对照组,差异有统计学意义(P<0.05);研究组血清miR-124水平高于对照组,血清miR-137水平低于对照组,差异均有统计学意义(P<0.05);研究组MOCA评分高于对照组,PDQ-39评分低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:普拉克索联合多巴丝肼治疗帕金森病患者可提高治疗总有效率、血清miR-124水平和MOCA评分,降低血清miR-137水平、NMSS评分和PDQ-39评分,改善Hoehn-Yahr分级,效果优于单纯多巴丝肼治疗。

加味三味汤治疗帕金森病非运动症状临床疗效

目的:探讨加味三味汤治疗帕金森病患者的非运动症状方面的临床疗效,以期获得更好的治疗效果及临床经验。方法:选取符合标准的50例帕金森病患者,随机分为对照组与实验组,每组各25例,对照组予以多巴丝肼片治疗;实验组在此基础上加用加味三味汤治疗,治疗一疗程后,比较两组患者的新版世界运动障碍学会帕金森病综合量表(MDS-UPDRS)中的日常生活非运动症状与运动症状量表中的震颤、动作迟缓、认知功能、焦虑、抑郁、饮水呛咳、夜尿、失眠、嗜睡、便秘、疲惫感、口角流涎十二项指标的综合评估。结果:在治疗前,两组患者所选取指标的综合评分没有统计学意义(P>0.05);治疗后,实验组患者的综合评分相较于对照组评分减少,有统计学意义(P<0.05)。并且两组患者的评分下降率也有统计学意义(P<0.01)。结论:加味三味汤可改善帕金森病患者的非运动症状,延缓病情进展。

从肝论治帕金森病非运动症状

基于肝的生理特点,从风、火、痰、瘀、虚五种病机证素对帕金森病非运动症状进行探讨。由于患者素体阴精不足,或阴血亏虚,阴虚不能制阳,阳亢化风;或肝郁克脾,脾运失司,痰湿内生;或肝气郁滞,阻碍血行;或痰瘀留滞经络而致病。阴精、肝血不足,筋脉失养为虚;痰浊、血瘀阻滞经络为实。治则以平肝滋阴、疏肝清热、理气化痰、活血养血为主,中药和针刺并用。肝风内扰,以平肝为主,兼以滋阴,选方镇肝熄风汤;肝火伤阴,以清热为主,兼以养阴,选方丹栀逍遥散;气滞痰阻,以理气为主,兼以化痰,选方柴胡加龙骨牡蛎汤;气滞血瘀,以理气为主,兼以活血,选方血府逐瘀汤;肝血亏虚,以补血为主,兼以柔肝,选方补肝汤。针刺辨病与辨证相结合,进行加减配穴。

帕金森病患者血清尿酸、同型半胱氨酸和胱抑素C水平与运动症状及认知功能的相关性

目的探讨帕金森病(Parkinson’s disease,PD)患者血清尿酸(uric acid,UA)、同型半胱氨酸(homocysteine,HCY)、胱抑素C(cystatin C,CysC)水平与PD患者的运动症状及认知功能的关系。方法选取2019年1月至2022年8月河北省人民医院收治PD患者200例。按照首发运动症状分为震颤(tremor-dominant,TD)组(n=104)和非震颤(non-tremor-dominant,NTD)组(n=96),依据蒙特利尔认知评估量表分为PD认知功能正常(cognitive normal in Parkinson’s disease,PD-CN)组(n=118)和PD认知功能障碍(cognitive impairment in Parkinson’s disease,PD-CI)组(n=82)。分别比较各组血清UA、HCY、CysC水平,采用多因素logistic回归分析PD患者TD和认知功能障碍的危险因素。结果与NTD组相比,TD组血清UA水平较高,Hcy、Cys C水平较低,差异均有统计学意义(P<0.05);多因素logistic回归分析结果显示,UA、HCY和Cys C是PD患者TD的独立危险因素。与PD-CI组相比,PD-CN组血清UA水平较高,HCY、Cys C水平较低,差异均有统计学意义(P<0.05);多因素logistic回归分析结果显示:UA、HCY和Cys C是PD患者认知功能障碍的独立危险因素(P<0.05)。结论PD患者血清UA、HCY、Cys C与运动症状和认知功能相关。

帕金森病患者妄想的研究进展

妄想被视为帕金森病患者最严重的精神症状之一。妄想不仅严重影响帕金森病患者的日常生活,还可能导致患者被安置在养老院或精神卫生专科医院,甚至增加其病死率。本文介绍了帕金森病患者妄想的概述、类别、评估工具和影响因素,并详细探讨了妄想对帕金森病患者及其照顾者造成的影响及可能的治疗与干预措施,为预防和改善帕金森病患者妄想的症状提供科学依据。未来研究应着重探索帕金森病患者妄想的影响因素,开发特异性评估工具,并制定针对性的干预策略,以更有效地应对这一挑战。

暖水燥土方治疗阳虚化风型帕金森病非运动症状的临床研究

目的 探讨暖水燥土方治疗帕金森病非运动症状的有效性和安全性,为帕金森病非运动症状患者选择合适的治疗方法提供临床数据支持。方法 将60例受试者随机分为治疗组和对照组,治疗前后的相关评定量表,具体有帕金森病评定量表Ⅲ(UPDRS Ⅲ)、Hoehn-Yahr(H-Y)分期、非运动症状筛查量表(NMSS)、帕金森病生活质量问卷-39(PDQ-39)。结果 治疗组和对照组治疗后UPDRSⅢ评分均明显下降(P <0.01),治疗组治疗后NMSS、PDQ-39评分明显下降(P <0.01),对照组治疗前后无统计学意义(P> 0.05),2组H-Y、UPDRS Ⅲ评分差异无统计学意义(P> 0.05),治疗组NMSS各症状评分睡眠疲劳、胃肠道功能、泌尿系统评分均明显下降(P <0.05),NMSS、PDQ-39有效率分别为63.3%、53.5%,疗效均高于对照组。结论 治疗组能有效改善帕金森病非运动症状,提高患者的生活质量,改善睡眠质量、胃肠道功能及泌尿情况。治疗组和对照组均能改善帕金森病患者病情程度,在改善运动症状方面,治疗组无明显优势。

帕金森病患者前庭诱发肌源性电位特点及其与姿势平衡障碍及非运动症状的相关性

目的:探讨帕金森病(PD)患者前庭诱发肌源性电位(VEMP)特点并分析其与姿势平衡障碍及非运动症状的相关性。方法:纳入2022年6月至2023年6月河北医科大学第一医院神经内科收治的65例原发PD患者及性别、年龄相匹配的60例健康体检者(HC),均进行VEMP检查,采用统一帕金森病评定量表(UPDRS)、Hoehn-Yahr分期量表(H-Y)评估患者的运动症状及疾病严重程度,采用蒙特利尔认知评价量表(MOCA)、简易智能状态检查量表(MMSE)、汉密尔顿抑郁量表24项(HAMD-24)、汉密尔顿焦虑量表14项(HAMA-14)、匹兹堡睡眠量表(PSQI)、快速眼动睡眠期行为障碍相关量表(RBD-SQ)、帕金森病睡眠障碍量表(PDSS)、自主神经功能量表(SCOPA-AUT)、简易疲劳量表(BFI)、国际不宁腿综合征量表(IRLS)、帕金森病疼痛量表(KPPS)、Wexner便秘评分(WCGS)评价患者的非运动症状,采用Berg平衡量表(BBS)、平衡信心量表(ABC)、Tinetti平衡与步态量表(Tinetti-POMA)评估患者的姿势平衡障碍。采用Spearman相关性分析探讨VEMP与其姿势平衡障碍及非运动症状的相关性。结果:PD患者VEMP异常率显著高于HC[72.31%(47/65)vs. 33.33%(20/60),χ^(2)=19.056,P<0.001],异常模式以反应缺失为主[58.46%(38/47)]。VEMP评分与PD患者病程、LEDD及各量表评分间的Spearman相关性分析显示,VEMP评分与BBS评分(r=-0.307,P=0.013)、Tinetti-POMA评分(r=-0.255,P=0.042)呈负相关关系,与HAMA-14评分(r=0.323,P=0.009)、RBD-SQ(r=0.476,P=0.001)评分呈正相关关系。结论:PD患者的VEMP异常率会显著升高,且异常模式以反应缺失为主,VEMP异常与PD患者的姿势平衡障碍、焦虑情绪严重程度及RBD严重程度具有显著相关性。VEMP作为一种无创、客观的神经电生理学指标,可为诊断PD的脑干功能受损情况提供依据,为前庭刺激及前庭康复等辅助治疗PD奠定理论基础。

7 T MRI对帕金森病扩大的血管周围间隙与运动症状的相关性研究

目的采用7 T MRI研究帕金森病(PD)病人扩大的血管周围间隙(EPVS)与其运动症状的相关性,探讨采用7 T MRI测量的EPVS在PD诊断中的价值。方法前瞻性纳入经临床确诊为PD的病人(PD组)14例,采用PD Hoehn-Yahr分期(H-Y分期)及统一PD评分量表(UPDRS)评估运动症状。同时纳入健康对照者(HC组)17例。2组均行7 T MRI检查,并在T_(2)WI和T_(2)-液体衰减反转恢复(FLAIR)影像上分析半卵圆中心和基底节区EPVS,计数并评分。采用独立样本t检验比较2组间半卵圆中心和基底节区EPVS的数量、评分之间的差异。采用Pearson相关分析评估PD病人半卵圆中心EPVS和基底节区EPVS评分及数量与运动症状评分的相关性。结果PD组的基底节区EPVS数量、半卵圆中心EPVS评分均高于HC组(均P<0.05)。PD病人的H-Y分期与基底节区EPVS数量呈正相关(r=0.242,P<0.001),其他运动症状评分与EPVS数量及评分均无相关性(均P>0.05)。结论7 T MRI上可见PD病人的EPVS比HC的多,且PD病人的运动症状与基底节区EPVS数量呈正相关,7 T MRI上测量的EPVS有可能作为PD的影像学标志物。